Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2025 07:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and...
November 17, 2025 10:26 ET | Source: Research and Markets

MRNA Vaccine Raw Materials Market - Global Forecast 2025-2030: Opportunities in Supply Chain Agility and Specialized Component Sourcing

Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccine Raw Materials Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.This comprehensive analysis...
November 14, 2025 09:00 ET | Source: Reading International Inc

Reading International Reports Third Quarter 2025 Results

Earnings Call Webcast to Discuss Third Quarter Financial Results Scheduled to Post to Corporate Website on Tuesday, November 18, 2025 NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Reading...
November 12, 2025 16:05 ET | Source: Tenax Therapeutics, Inc.

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2,...
November 10, 2025 14:11 ET | Source: Neuro Sharp

Neuro Sharp Unveiled: Exploring the Science Behind This Neuro Sharp Brain Health Supplement for Focus, Memory, and Mental Clarity

New York City, NY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intro In a significant development for the cognitive wellness industry, Neuro Sharp, a scientifically formulated brain health supplement,...
November 10, 2025 08:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR...
November 06, 2025 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under...
November 06, 2025 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals announces first patient randomized in Phase 2b FORTITUDE-HCM trial of ninerafaxstat for non-obstructive hypertrophic cardiomyopathy.
November 06, 2025 07:00 ET | Source: Tenax Therapeutics, Inc.

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...
November 06, 2025 06:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories,...